Factor XIII

Human blood coagulation Factor XIII B subunit

(hFXIII B, recombinantly produced in insect cells)

200 µg 400 € available

Art. No. T050
Synonym Recombinant Fibrin stabilizing factor B subunit

recombinant Factor XIII B subunit T050 by Zedira
Molecular Weight 80 kDa (monomer)
Source Recombinantly produced in insect cells
Purity > 95% [by SDS-PAGE]
Appearance White lyophilized solid.
Description Recombinant human Factor XIII B subunit is a carrier protein for blood coagulation Factor XIII A subunit. Factor XIII B subunit is a typical mosaic protein and consists of 10 tandem repeats, called “sushi”-domains. Its function is to protect Factor XIII A subunit from slow spontaneous activation and clearance.
Reagents The recombinant human Factor XIII B subunit is lyophilized from 20 mM Tris-HCl pH 6.8, 150 mM NaCl, 1 mM EDTA.
Reconstitution Add the volume of H2O the protein is lyophilized from (see Certificate of Analysis) to the vial of lyophilized powder. Rotate vial gently until solid dissolves. After reconstitution the solution should be stored frozen in working aliquots. Keep cooled on ice for short term storage.
Application Factor XIII B subunit is a carrier protein. The recombinantly expressed protein is able to form a heterotetrameric complex with recombinant Factor XIII A from human, as well as the analogous proteins from pig, dog, mouse, and rat as shown by native PAGE below (Heil et al., 2013). Accordingly, the protein may be used for biochemical studies understanding the physiological function of FXIII, for example determination of the binding constant between Factor XIII A and B subunit (Katona et al., 2014).
Storage Storage for several months is possible at > - 20°C.
Delivery is possible at ambient temperature
Reference(s) Böhm et al., J. Med. Chem. 2014, 57:10355-65
Heil et al., Thromb. Res., 2013, 131, e214–e22
Katona et al., Blood, 2014, 123, 1757-63


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of non-alcoholic fatty liver disease (NAFLD)
  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy